| 1. |
|
|
| 2. |
- Archer, Trevor, 1949
(author)
-
Effects of Exogenous Agents on Brain Development: Stress, Abuse and Therapeutic Compounds.
- 2010
-
In: CNS neuroscience & therapeutics. - : Wiley. - 1755-5949 .- 1755-5930.
-
Journal article (peer-reviewed)abstract
- SUMMARY The range of exogenous agents likely to affect, generally detrimentally, the normal development of the brain and central nervous system defies estimation although the amount of accumulated evidence is enormous. The present review is limited to certain types of chemotherapeutic and "use-and-abuse" compounds and environmental agents, exemplified by anesthetic, antiepileptic, sleep-inducing and anxiolytic compounds, nicotine and alcohol, and stress as well as agents of infection; each of these agents have been investigated quite extensively and have been shown to contribute to the etiopathogenesis of serious neuropsychiatric disorders. To greater or lesser extent, all of the exogenous agents discussed in the present treatise have been investigated for their influence upon neurodevelopmental processes during the period of the brain growth spurt and during other phases uptill adulthood, thereby maintaining the notion of critical phases for the outcome of treatment whether prenatal, postnatal, or adolescent. Several of these agents have contributed to the developmental disruptions underlying structural and functional brain abnormalities that are observed in the symptom and biomarker profiles of the schizophrenia spectrum disorders and the fetal alcohol spectrum disorders. In each case, the effects of the exogenous agents upon the status of the affected brain, within defined parameters and conditions, is generally permanent and irreversible.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Moloney, Teresa C., et al.
(author)
-
Heat Shock Protein 70 Reduces alpha-Synuclein-Induced Predegenerative Neuronal Dystrophy in the alpha-Synuclein Viral Gene Transfer Rat Model of Parkinson's Disease
- 2014
-
In: CNS Neuroscience & Therapeutics. - : Wiley. - 1755-5949 .- 1755-5930. ; 20:1, s. 50-58
-
Journal article (peer-reviewed)abstract
- AimsIt has become increasingly evident that the nigrostriatal degeneration associated with Parkinson's disease initiates at the level of the axonal terminals in the putamen, and this nigrostriatal terminal dystrophy is either caused or exacerbated by the presence of -synuclein immunopositive neuronal inclusions. Therefore, strategies aimed at reducing -synuclein-induced early neuronal dystrophy may slow or halt the progression to overt nigrostriatal neurodegeneration. Thus, this study sought to determine if adeno-associated virus (AAV) mediated overexpression of two molecular chaperone heat shock proteins, namely Hsp27 or Hsp70, in the AAV--synuclein viral gene transfer rat model of Parkinson's disease could prevent -synuclein-induced early neuronal pathology. MethodsMale Sprague-Dawley rats were intranigrally coinjected with pathogenic (AAV--synuclein) and putative therapeutic (AAV-Hsp27 or AAV-Hsp70) viral vectors and were sacrificed 18weeks postviral injection. ResultsIntranigral injection of AAV--synuclein resulted in significant -synuclein accumulation in the substantia nigra and striatal terminals which led to significant dystrophy of nigrostriatal dopaminergic neurons without overt nigrostriatal neurodegeneration. Coinjection of AAV-Hsp70, but not AAV-Hsp27, significantly reduced AAV--synuclein-induced neuronal dystrophy. ConclusionsThese data confirm that overexpression of Hsp70 holds significant potential as a disease-modulating therapeutic approach for Parkinson's disease, with protective effects against early-onset -synuclein-induced pathology demonstrated in the AAV--synuclein model.
|
|
